Engineered immune cells take on childhood brain cancer
NCT ID NCT06946680
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This early-phase study tests a new treatment for children and young adults with aggressive brain tumors called high-grade glioma and DIPG. The therapy uses the patient's own immune cells, modified to better find and attack the tumor. The main goals are to see if the treatment is safe and possible to make for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Florida Health Children's Hospital
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.